Benlysta 200 mg solution for injection in pre-filled pen.
219855
Phase 3 small_molecule active
Quick answer
Benlysta 200 mg solution for injection in pre-filled pen. for connective tissue diseases is a Phase 3 program (small_molecule) at GlaxoSmithKline Biologicals S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline Biologicals S.A.
- Indication
- connective tissue diseases
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active